<DOC>
	<DOCNO>NCT00379587</DOCNO>
	<brief_summary>The purpose trial determine administration rituximab allogeneic stem cell transplantation reduce incidence chronic GVHD . Chronic GVHD medical condition occur bone marrow stem cell transplant form one individual another . After transplant , donor immune system may recognize recipient body foreign may attempt `` reject '' body . Rituximab drug interferes immune system function specifically target B cell kill .</brief_summary>
	<brief_title>Rituximab Prevention Chronic GVHD</brief_title>
	<detailed_description>Study Design : The study design Phase II , open label trial Rituximab chronic GVHD prophylaxis HLA-matched , relate unrelated peripheral blood stem cell transplantation ablative non-ablative conditioning . Primary Objective : To determine incidence clinically extensive chronic GVHD one two year allogeneic stem cell transplantation single dose Rituximab administer 100 day , 6 month , 9 month 1 year transplantation chronic GVHD prophylaxis . Secondary Objectives : To determine incidence adverse hematological event , incidence infectious complication , rate malignant relapse , effect donor hematopoietic chimerism Rituximab administration . Eligibility Criteria : Eligible patient 18 year age great undergone non-myeloablative fully ablative transplantation HLA-matched ( 6/6 locus ) single antigen/allele mismatch ( 5/6 ) donor approximately 100 day ago . Adequate performance status organ function confirm prior enrollment . No ongoing infection acute GVHD present time enrollment . Evidence sustain donor chimerism confirm prior study entry . Treatment Description : Chronic GVHD prophylaxis consist Rituximab 375 mg/m2 administer 100 day , 6 , 9 12 month transplantation . Accrual Objective : 68 patient accrued 12 month . Study Duration : Patients evaluate two year time transplantation evaluation primary secondary endpoint . Subjects follow longitudinally completion study period determination clinical status .</detailed_description>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients undergo either ablative nonmyeloablative allogeneic stem cell transplantation Peripheral blood stem cell must use stem cell source Patients must receive transplantation donor identical 6 HLA locus , mismatch 1 locus . Patients undergone nonmyeloablative stem cell transplant must &gt; 80 % donor hematopoiesis within 30 day study enrollment 18 year age old Performance Status 02 Life expectancy &gt; 100 day Subjects CLL eligible , 20 % residual leukemia bone marrow time study entry Evidence relapse residual malignancy within 30 day trial entry Highly aggressive B cell malignancy , Burkitt 's lymphoma Burkitt'slike lymphoma Allogeneic stem cell transplantation use single multiple umbilical cord blood unit use bone marrow Evidence active uncontrolled infection , evidence natural exposure Hepatitis B , Hepatitis C HIV Evidence ongoing gastrointestinal hepatic acute GVHD , evidence great ongoing Stage I cutaneous acute GVHD GVHD chronic feature diagnose prior day +100 prior enrollment Participation clinical trial evaluate another preventative strategy chronic GVHD , ongoing participation clinical trial therapy acute GVHD No Donor Lymphocyte Infusion ( DLI ) prior day 100 plan DLI upcoming 30 day Heart failure uncontrolled medication Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>Chronic GVHD</keyword>
</DOC>